Skip to main content
. 2016 Jan 21;114(3):281–289. doi: 10.1038/bjc.2015.453

Figure 1.

Figure 1

Flow chart showing study enrolment, withdrawals and exclusions. Concerns about starting a new drug with potential gastrointestinal side effects, inability to adhere to strict follow-up procedures and psychological distress at their recent cancer diagnosis were the most common reasons given for declining participation in the study.